The GI Cancer Institute and the AGITG work together to raise funds and awareness of gastro-intestinal (GI) cancer and clinical trials, and to develop and deliver rigorous best practice clinical trials for Gastro-Intestinal cancer patients. Since 1991, our key priority has been to undertake research that is centred on patient care and to improve medical care and practice in the treatment of GI cancer. Our clinical trials allow us to find better ways to treat GI cancers. This has seen improvement in both the life expectancy and quality of life of people diagnosed with these cancers over the last 30 years. GI cancers include those of the oesophagus, stomach, liver, gall bladder, pancreas, small intestine, bowel and anus. GI cancers are the most common form of cancer, directly affecting more than 33,200 Australians each year and claiming a devastating 37 lives each day. The multi-disciplinary AGITG membership encompasses medical oncologists, radiation oncologists, surgeons, statisticians, data managers, allied health care professionals and consumers. The GI Cancer Institute is a not-for-profit organisation that saves lives by funding GI cancer research, conducted by the AGITG. Through regular appeals, community fundraising events, bequests, in memory giving, and philanthropic support, the GI Cancer Institute funds small-scale AGITG trials to improve outcomes for people with GI cancer.